A Dow Jones Newswires story covers personalized medicine with profiles of companies, including Sequenom and Helicos, that push diagnostic tests for biomarkers. It's the expected growth in this arena that led to Invitrogen's $6.7 billion acquisition of Applied Biosystems, the article says; more deals are likely in the offing. The story quotes analyst Arthur Henderson as saying, "There is a lot of competition for deals; it is going to increase. ... The sky is the limit in terms of opportunity."